Raymond James Initiates Coverage of Palisade Bio with Outperform
Fintel reports that on October 9, 2026, Raymond James initiated coverage of Palisade Bio (NASDAQCM:PALI) (DB:7NS0) with a Outperform recommendation.
Palisade Bio, Inc. is a biopharmaceutical company based in the United States, primarily focused on the development of therapeutics to address acute and chronic gastrointestinal (GI) complications stemming from post-operative digestive enzyme damage. The company is chiefly engaged in advancing its portfolio through clinical trials aimed at enhancing recovery and preventing complications following GI surgery. One of their key projects includes the development of an investigational drug, LB1148, which is designed to accelerate the return of GI function post-surgery, potentially reducing the need and associated risks of intravenous nutrition and opioids. This focus is part of Palisade Bio’s broader strategy to address significant unmet medical needs in post-operative care.
The latest closing price of Palisade Bio on October 8, 2026, was $1.45. This price represents a price change of +1.40% over one week, compared to the baseline close of $1.43 on October 1, 2026. Over a one-month period, the stock has experienced a price change of -34.09% from its baseline close of $2.20 on September 8, 2026. In its latest earnings report dated August 10, 2026, Palisade Bio reported an actual EPS of -0.05, compared to an estimated EPS of -0.0533. The company reported actual revenue of $500,000.00 for the period, compared to the revenue estimate of $0.00.
Separate from Raymond James's individual rating, aggregate market consensus data shows a current consensus target mean of $10.61 and a median of $8.16 as of October 2, 2026. This target represents an implied change of +631.59% from the stock's recent valuation. In terms of broader analyst sentiment, the current recommendation period as of September 1, 2026, shows a total of 16 recommendations, consisting of 6 strong buy, 9 buy, and 1 hold recommendations. This distribution results in a positive recommendation percentage of 93.8% and a hold percentage of 6.3%. Additionally, on September 23, 2026, HC Wainwright & Co. reiterated its Buy rating for Palisade Bio, maintaining its Buy recommendation.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| October 9, 2026 | Raymond James | Outperform | initiated coverage | |
| September 23, 2026 | HC Wainwright & Co. | Buy | Buy | reiterated |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.